

1 Prevalence of Bacterial Coinfection and Patterns of Antibiotics  
2 Prescribing in Patients with COVID-19: A Systematic review and  
3 Meta-Analysis

4  
5

6 Faisal Salman ALSHAIKH<sup>a,b</sup>, Oula Nawaf SINDI<sup>a</sup>, Brian GODMAN<sup>a,c,d</sup>, R Andrew  
7 SEATON<sup>d,e</sup>, Amanj KURDI<sup>g,h,a,d</sup>

8

9 <sup>a</sup>Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of  
10 Strathclyde, Glasgow, UK; [ph.faisalalshaiikh@gmail.com](mailto:ph.faisalalshaiikh@gmail.com); [oula.nawaf@gmail.com](mailto:oula.nawaf@gmail.com)

11 <sup>b</sup> Pharmaceutical Services, Bahrain Defence Force Military Hospital, Kingdom of Bahrain

12 <sup>c</sup> Centre of Medical and Bio-allied Health Sciences Research, Ajman University, United Arab  
13 Emirates

14 <sup>d</sup>Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako  
15 Makgatho Health Sciences University, Pretoria, South Africa

16 <sup>e</sup>Queen Elizabeth University Hospital, Glasgow, UK

17 <sup>f</sup>Scottish Antimicrobial Prescribing Group, Healthcare Improvement Scotland, Glasgow, UK

18 <sup>g</sup>Center of Research and strategic studies, Lebanese French University, Erbil, Kurdistan  
19 Region Government, Iraq

20 <sup>h</sup>Department of Pharmacology and Toxicology, College of Pharmacy, Hawler Medical  
21 University, Erbil, Kurdistan Region Government, Iraq

22

23

24

25

26

27 **Corresponding Author:**

28

29 Faisal Alshaiikh

30

31 Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, 161  
32 Cathedral Street, Glasgow, G4 0RE, Scotland, UK

33

34 **Email:** [ph.faisalalshaiikh@gmail.com](mailto:ph.faisalalshaiikh@gmail.com)

35 **Telephone:** (00973)36805888

36

37 **Co-corresponding Author:**

38

39 Brian Godman

40

41 **Email:** [briangodman@outlook.com](mailto:briangodman@outlook.com)

42

43 **Word Count:** 3583

44

45 **Number of Tables:** 1

46

47 **Number of Figures:** 7

48

49

## 50 **Abstract**

51

52 *Background:* Evidence around prevalence of bacterial coinfection and pattern of antibiotic  
53 use in COVID-19 is controversial although high prevalence rates of bacterial coinfection  
54 have been reported in previous similar global viral respiratory pandemics. Early data on the  
55 prevalence of antibiotic prescribing in COVID-19 indicates conflicting low and high  
56 prevalence of antibiotic prescribing which challenges antimicrobial stewardship programmes  
57 and increases risk of antimicrobial resistance (AMR).

58 *Aim:* To determine current prevalence of bacterial coinfection and antibiotic prescribing in  
59 COVID-19 patients

60 *Data Source:* OVID MEDLINE, OVID EMBASE, Cochrane and MedRxiv between January  
61 2020 and June 2021.

62 *Study Eligibility:* English language studies of laboratory-confirmed COVID-19 patients  
63 which reported (a) prevalence of bacterial coinfection and/or (b) prevalence of antibiotic  
64 prescribing with no restrictions to study designs or healthcare setting

65 *Participants:* Adults (aged  $\geq 18$  years) with RT-PCR confirmed diagnosis of COVID-19,  
66 regardless of study setting.

67 *Methods:* Systematic review and meta-analysis. Proportion (prevalence) data was pooled  
68 using random effects meta-analysis approach; and stratified based on region and study  
69 design.

70 *Results:* A total of 1058 studies were screened, of which 22, hospital-based studies were  
71 eligible, comprising 76,176 of COVID-19 patients. Pooled estimates for the prevalence of  
72 bacterial co-infection and antibiotic use were 5.62% (95% CI 2.26 – 10.31) and 61.77% (CI  
73 50.95 – 70.90), respectively. Sub-group analysis by region demonstrated that bacterial co-  
74 infection was more prevalent in North American studies (7.89%, 95% CI 3.30-14.18).

75 *Conclusion:* Prevalence of bacterial coinfection in COVID-19 is low, yet prevalence of  
76 antibiotic prescribing is high, indicating the need for targeted COVID-19 antimicrobial  
77 stewardship initiatives to reduce the global threat of AMR.

78

79

80

81

82 **Keywords:** COVID-19, SARS-CoV-2, Bacterial Coinfection, Antibiotic Prescribing,  
83 Antibiotics

84

## 1- Introduction

The first case of COVID-19 was reported in December 2019<sup>[1, 2]</sup>. Since its emergence, the novel severe acute respiratory coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic. As of January 14th 2022, a total of 318 million confirmed cases have been reported, with 5.5 million confirmed deaths<sup>[3]</sup>. The pandemic has overwhelmed healthcare systems globally and proved to be a challenge to healthcare professionals in providing optimum healthcare with limited evidence of effective treatment approaches certainly initially with potential treatments including hydroxychloroquine, lopinavir/ritonavir and remdesivir subsequently found to have limited impact in reducing morbidity and mortality in hospitalised patients in large clinical trials<sup>[4, 5]</sup>. In fact in the initial studies only dexamethasone was shown to reduce mortality among patients with COVID-19 who were receiving either invasive mechanical ventilation or oxygen alone<sup>[6]</sup>.

Alongside concerns with misinformation concerning potential treatments for patients with COVID-19 including hydroxychloroquine and the subsequent impact on morbidity, mortality and costs<sup>[7, 8]</sup>, the presence of bacterial co-infection in COVID-19 has been a widespread concern amongst healthcare professionals due to overlapping clinical features with bacterial pneumonia<sup>[9]</sup>, and the increased risk of morbidity and mortality associated with bacterial co-infections<sup>[10]</sup>. The presence of bacterial co-infection had been observed during previous viral pandemics including the 1918 influenza pandemic and the 2009 influenza A (H1N1) pandemic<sup>[11, 12]</sup>, with *S. pneumoniae*, *β-hemolytic streptococci*, *H. influenzae*, and *S. aureus*, being the most common causative pathogens of respiratory tract infections<sup>[13]</sup>. During winter months influenza-associated bacterial infections may account for up to 30% of community acquired pneumonia cases (CAP)<sup>[14]</sup>. Nevertheless, other respiratory viruses such as Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-1 have reported a very low prevalence of bacterial co-infection amongst infected patients<sup>[15, 16]</sup> potentially attributable to the comparatively small number of cases reported<sup>[17]</sup>.

Concerns regarding bacterial co-infection in COVID-19 patients has led to widespread use of antibiotics empirically in both hospital and community settings<sup>[18-22]</sup>. The significant increase in antibiotic prescribing during the pandemic challenges antimicrobial stewardship programmes and risks emergence of multi-drug resistant bacteria<sup>[23-25]</sup>, with their associated impact on morbidity, mortality and costs<sup>[26-29]</sup>.

Prior meta-analyses suggest a bacterial coinfection prevalence of <4% - 8% in patients with COVID-19, nonetheless, these studies included a small number of patients<sup>[9, 30-32]</sup>. The prevalence of antibiotic prescribing in patients with COVID-19 was 74.6%, reported in a prior meta-analysis, which included literature mostly from Asia<sup>[33]</sup>. Consequently, this review aims at building on these publications through identifying the prevalence of bacterial co-infection, and the prevalence of antibiotic use in patients with COVID-19 across multiple countries and regions to guide future prescribing. This includes reducing the inappropriate use of antimicrobials during the COVID-19 pandemic where inappropriate use is a potential driver of antimicrobial resistance (AMR)<sup>[24, 25, 34]</sup>

## 129           **2- Method**

130

### 131           *Search Strategy*

132

133           Electronic databases were systematically searched for published literature reporting bacterial  
134           coinfection and/or antibiotic use in patients with COVID-19. The databases searched  
135           included OVID MEDLINE, OVID EMBASE, Cochrane library and MedRxiv, with articles  
136           published between December 2019 and 29<sup>th</sup> June 2021. The search terms and keywords used  
137           included terms related to “COVID-19”, “Coinfections” and “Antibiotics” (*Appendix 1*). The  
138           results of the search conducted were imported into Covidence online software for systematic  
139           reviews, in which duplicate publications were removed. Reporting was based on the Preferred  
140           Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for  
141           systematic reviews. The study protocol was registered in the international register of  
142           systematic reviews, PROSPERO, under the following ID: CRD42021261734

143

### 144           *Study Selection*

145

146           Two reviewers (FA and ON) independently screened titles and abstracts and read full texts to  
147           assess if they met the pre-set inclusion criteria, disputes were settled by third a reviewer  
148           (AK). All English language articles, irrespective of their primary outcomes, reporting  
149           bacterial coinfection rate and/or antibiotics use in, laboratory-confirmed (via Reverse  
150           transcription polymerase chain reaction (RT- PCR)), COVID-19 human adult patients ( $\geq 18$   
151           years) in all healthcare settings were included (Outpatients and Inpatients). Studies in which  
152           patients with suspected COVID-19, based on clinical symptoms and not laboratory confirmed  
153           RT-PCR, were excluded. No restrictions to study design were applied. Case reports, case  
154           notes, editorials, letters, systematic review, meta-analysis and qualitative studies were  
155           excluded. Abstract only publications with no full text were also excluded.

156

157           Non-peer reviewed/ Pre-prints publications on MedRxiv were also included if the papers  
158           contained relevant information regarding the topic of interest.

159

160

### 161           *Data Extraction and quality assessment*

162

163           Data was extracted into a standardised collection form that was created using Microsoft Excel  
164           2016, by reviewers FA and ON. Data collected for information regarding the demographics  
165           of the studies included the following variables: first author; publication year; country of  
166           publication; study design (Retrospective, prospective, RCTs etc...); is the study multicentre;  
167           study setting (Community, hospital, mixed etc...); if the study was peer-reviewed; number of  
168           positive COVID-19 patients; proportion of male population; and the average age. Data was  
169           collected for the following variables: prevalence of bacterial coinfection (defined as a  
170           bacterial coinfection within 48 hours of positive COVID-19 diagnosis and hospital  
171           admission), studies looking into super-infection and/or secondary-infection (occurring at 48  
172           hours of hospital admission), were not included; and prevalence of antibiotic use among  
173           COVID-19 patients. The following information, if reported, was also collected: bacterial  
174           species isolated; the prevalence of most common bacteria; most common site of infection of

175 bacterial infection; clinical outcomes of co-infected patients; antibiotic class prescribed;  
176 timing of antibiotic initiation in relation to COVID-19 onset and clinical outcomes of patients  
177 prescribed antibiotics. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of  
178 the observational studies included in the review<sup>[35]</sup>.

179

180

### 181 ***Data Synthesis, sensitivity analysis and publication bias***

182


183 The two primary outcomes were the prevalence of bacterial coinfection in COVID-19  
184 patients and the prevalence of antibiotics use in COVID-19 patients. Further sub-group  
185 analysis was conducted based on studies' region/continent and design. Proportion  
186 (prevalence) outcome data across all studies were pooled using a random effect meta-analysis  
187 with Freeman and Tukey method<sup>[36]</sup>. Results were presented using forest plots, to  
188 demonstrate the studies' effect size, and 95% confidence intervals (CI). Heterogeneity was  
189 assessed using  $I^2$  statistic. A value below 40% was considered to be low heterogeneity, 30 –  
190 60% was considered to be moderate heterogeneity, 50-90% was substantial, and 75-100% is  
191 considerable heterogeneity<sup>[37]</sup>. Publication bias was assessed through Funnel plots followed  
192 by Egger's asymmetry test<sup>[38]</sup>. All analyses were carried out using STATA/BE 17.0 for  
193 Windows (64-bit x 86-64) using the *Metaprop* command package.

194

### 3- Results

195  
196  
197  
198  
199  
200  
201  
202  
203

A total of 1183 studies were identified and 125 duplicates were removed. A total of 1058 studies were screened for title and abstract, 81 were screened by full-text screening and 22 studies were eligible for inclusion in the final analysis<sup>24-45</sup> (*figure 1*). Prevalence of bacterial coinfections was reported in 20 of the 22 studies included, whilst prevalence of antibiotics use was reported in 18 studies only (*table 1*).



204  
205  
206

*Figure 1.* Study flow diagram based on PRISMA guidelines

Author, Year	Country	Study Design	Multicentre? (Y/N)	Study Setting	Peer-reviewed? (Y/N)	Quality Rating	COVID-19 Patients, n	Male, n (%)	Age (SD/IQR)	Bacterial Coinfection, n (%)	Most common Bacteria, N (%)	Antibiotic Use, N (%)	Antibiotic Class (most common)
1. Puzniak L, 2021 <sup>[39]</sup>	USA	Retrospective Cohort	Y	Hospital	Y	Good	17003	9026 (53)	61.7 (18)	2889 (16.99)	<i>Enterobacteriales</i> , 1594 (55.17)	11562 (68)	Cephalosporins
2. Wang L, 2020 <sup>[40]</sup>	UK	Retrospective Cohort	Y	Hospital	Y	Good	1396	903 (65)	67.4 (16.2)	37(2.65)	<i>E. Coli</i> , 6 (16.22)	36 (2.58)	
3. Michael S, 2020 <sup>[41]</sup>	USA	Retrospective Cohort	Y	Hospital	Y	Good	73	35 (48)				27 (36.99)	NR
4. S. Hughes, 2020 <sup>[42]</sup>	UK	Retrospective Cohort	Y	Hospital	Y	Good	836	519 (62)	69 (55-81)	27 (3.23)	<i>S. aureus</i> , 4 (14.81)		
5. Contou D, 2020 <sup>[43]</sup>	France	Retrospective Cohort	N	Hospital	Y	Good	92	73 (79)	61 (55-70)	26 (28.26)	<i>S. aureus</i> , 10 (38.46)	39 (42.39)	Cephalosporins
6. Cheng, L, 2020 <sup>[44]</sup>	China	Retrospective Cohort	Y	Hospital	Y	Good	147	85 (58)	36 (24-54)	4 (2.72)		52 (35.37)	Cephalosporins
7. Neto A G M,2020 <sup>[45]</sup>	USA	Retrospective Cohort	N	Hospital	Y	Good	242	123 (51)	66 (14.75)	46 (19.01)	<i>E. Coli</i> , 12 (26.09)	162 (66.94)	Cephalosporins
8. Lardaro T, 2020 <sup>[46]</sup>	USA	Retrospective Cohort	Y	Hospital	Y	Good	542	269 (50)	62.8 (16.5)	20 (3.69)	<i>S. aureus</i> , 7 (35)		
9. Chen S, 2020 <sup>[47]</sup>	China	Retrospective Cohort	N	Hospital	Y	Good	408	196 (48)	48 (34-60)	25 (6.13)	<i>mycoplasma pneumonia</i> , 13 (52)	60 (14.71)	NR
10. Baskar V, 2021 <sup>[48]</sup>	UK	Retrospective Cohort	Y	Hospital	Y	Good	254	164 (65)	59 (49-69)	14 (5.51)	<i>S. aureus</i> , 4 (28.57)		
11. Russell C D, 2021 <sup>[49]</sup>	UK	Prospective Cohort	Y	Hospital	Y	Good	48902	28116 (58)	74 (59-84)	318 (0.65)	<i>E. Coli</i> , 64 (20.13)	39528 (80.83)	Penicillin/B-lactams
12. Lehmann C J,2021 <sup>[50]</sup>	USA	Retrospective Cohort	N	Hospital	Y	Poor	321	155 (48)	60 (17)	7 (2.18)	<i>S. aureus</i> , 2 (28.57)	222 (69.16)	NR
13. Vaughn V,2021 <sup>[51]</sup>	USA	Retrospective Cohort	Y	Hospital	Y	Good	1705	885 (52)	64.7 (53-77)	59 (3.46)		965 (56.6)	Cephalosporins
14. Miao Q, 2021 <sup>[52]</sup>	China	Retrospective Cohort	N	Hospital	Y	Good	323			17 (5.26)	<i>Klebsiella pneumonia</i> , 11 (64.71)		
15. Karami Z, 2020 <sup>[53]</sup>	Netherlands	Retrospective Cohort	Y	Hospital	Y	Good	925	591 (64)	70 (59-77)	7 (0.76)	<i>S. aureus</i> , 4 (57.14)	556 (60.11)	Cephalosporins
16. Garcia-Vidal C ,2021 <sup>[54]</sup>	Spain	Retrospective Cohort	N	Hospital	Y	Good	989	552 (56)	62 (48-74)	31 (3.13)	<i>Streptococcus pneumonia</i> , 12 (38.71)	917 (92.72)	Macrolide
17. Crotty M P, 2020 <sup>[55]</sup>	USA	Prospective Cohort	Y	Hospital	N	Good	289		58.6 (14.4)	25 (8.65)	<i>S. aureus</i> , 5 (20)	271 (93.77)	NR
18. Wei W, 2020 <sup>[56]</sup>	USA	Prospective Cohort	N	Hospital	N	Good	147	87 (59)	52			87 (59.18)	Cephalosporins
19. Karaba S, 2020 <sup>[57]</sup>	USA	Prospective Cohort	Y	Hospital	Y	Good	1016	543 (53)	62 (48-74)	53 (5.22)		717 (70.57)	NR
20. Martin A, 2020 <sup>[58]</sup>	USA	Retrospective Cohort	Y	Hospital	N	Good	208	105 (51)	69 (60-80)	24 (11.54)	<i>S. aureus</i> , 5 (20.83)	172 (82.69)	Cephalosporins
21. Rothe K, 2021 <sup>[59]</sup>	Germany	Retrospective Cohort	N	Hospital	Y	Good	140	90 (64)	63.5 (17-99)	3 (2.14)		116 (82.86)	Penicillin/B-lactams
22. Asmarawati T P, 2020 <sup>[60]</sup>	Indonesia	Retrospective Cohort	N	Hospital	Y	Good	218	120 (55)	52.45 (14.44)	13 (5.96)	NR	164 (75.23)	Quinolones

**Table 1.** Summary of study and patients' characteristics

207 ***Study characteristics***

208

209 Retrospective cohort studies accounted for the majority of the studies involved (n = 18, 81%),  
210 whilst prospective cohort studies accounted for the remaining (n=4, 18%). Of the 22 studies  
211 included, 3 (13%) studies were pre-prints <sup>[55, 56, 58]</sup>, whilst the remaining (n=19, 86%) were  
212 peer-reviewed. A total of 13 (59%) studies were conducted in multicentre settings, whilst the  
213 remainder (n=9, 40%) were conducted in single centre settings. All of the studies included  
214 were conducted in hospital settings, whether it be in a normal, isolation or an intensive care  
215 ward. Twenty one out of the 22 studies have been classified as a “Good” rating during the  
216 quality assessment process.

217

218 ***Geographical distribution***

219

220 The majority of the studies included in the review took place in the United States of America  
221 (USA) (n=10, 45%), followed by the United Kingdom (UK) (n=4, 18%), China (n=3, 14%)  
222 and 1 study each in France, Germany, Indonesia, The Netherlands and Spain. Continent-wise,  
223 10 (45%) studies were from North America, 8 (36%) from Europe and 4 (18%) were from  
224 Asia.

225

226 ***Patients Characteristics***

227

228 A total of 76,176 adult patients with RT-PCR confirmed COVID-19 were included from 22  
229 studies, with studies by Russell *et al*<sup>[49]</sup> (UK, 48,902 patients) and Puzniak *et al*<sup>[39]</sup> (US,  
230 17,003 patients) comprising 86.5% of the overall study population. The mean age of patients,  
231 was 61 years (IQR 59-67, range 36-74) and mean proportion of male subjects was 54% (IQR  
232 50-63).

233

234 The most commonly used class of antibiotics were the cephalosporins (8 out of 18 studies),  
235 with 7 out of 18 of the studies reporting that antimicrobial use was initiated on admission.

236

237 ***Meta-analysis of prevalence of bacterial coinfection in COVID-19 patients***

238

239 A total of 20 studies of the 22 studies included in this review, comprising of 75,956 (99.7%)  
240 of the overall study population, investigated bacterial co-infection. Of which, only 3,645  
241 (4.7%) patients were reported to have a confirmed diagnosis of bacterial co-infection. The  
242 random effects meta-analysis of all combined studies estimated that the prevalence of  
243 bacterial coinfection in COVID-19 patients was 5.62% (95% CI 2.26 – 10.31), with an  $I^2$   
244 value of 99.69%, indicating considerable heterogeneity (**Figure 2**).

245


246 Of all the 20 studies (90%) reporting on bacterial coinfection, the most commonly reported  
247 bacterial organism was *S. aureus* (n=8, 40%), followed by *E.coli* (n=3, 15%). The most  
248 common source of bacterial coinfection was respiratory (n=10, 50%), followed by blood  
249 (n=2, 10%) and urine (n=2, 10%).

250

251



252



253

254

**Figure 2.** Prevalence of Bacterial coinfection


255

### 256 **Bacterial coinfection by Region**

257

258 The prevalence of bacterial coinfection was highest in North America (7.89%, 95% CI 3.30-  
 259 14.18), followed by Asia (5.3%, 95% CI 4.03 – 6.73), with Europe having the lowest  
 260 prevalence (3.57%, 95% CI 1.72 -6) (**Figure 3**). Heterogeneity was considerable in both  
 261 North America and Europe,  $I^2 = 98.89\%$  and  $96.75\%$  respectively. Studies in Asia had low  
 262 heterogeneity with an  $I^2$  value of 0%.

263




264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274

**Figure 3.** Prevalence of Bacterial coinfection by region

**Bacterial coinfection by study design**

Retrospective cohort studies had the highest prevalence of bacterial coinfection (5.92%, 95% CI 2.79 – 10.07), whilst prospective cohort studies had a prevalence of 3.97% (95% CI 0.38, 10.92) (**Figure 4**). Heterogeneity was considerable in both retrospective and prospective,  $I^2 = 98.88\%$  and  $98.62\%$  (**Appendix Fig. A**) respectively.

275



276

**Figure 4.** Prevalence of Bacterial coinfection by study design

277

278

279 **Meta-analysis of antibiotic use in COVID-19 patients**

280


281 Antibiotic use was reported in 55,653 of the total 76,176 patients included in this review,  
 282 with 18 studies (81%) reporting antibiotic use in COVID-19 patients. The random effects  
 283 meta-analysis of all combined studies have estimated a prevalence of 61.16% (CI 50.95 –  
 284 70.90) of antibiotic prescribing in COVID-19, with an  $I^2$  value of 99.77%, indicating  
 285 considerable heterogeneity (**Figure 5**).

286

287

288

289



290

291

292

**Figure 5.** Antibiotic use

293

**Antibiotic use by region**

294

295

296

297

298

299

300


301

302

303

North America had the highest antibiotic use in COVID-19 patients per region (68.84%, 95% CI 62.27 – 75.05), followed by Europe (60.01%, 95% CI 25.50- 89.67), with Asia having the lowest prevalence of antibiotic use (40.81%, 95% CI 7.75 – 79.65) (**Figure 6**). Heterogeneity was considerable across all with studies in Europe being the most heterogeneous ( $I^2 = 99.91\%$ ), followed by Asia ( $I^2 = 99.18\%$ ) (**Appendix Fig. B**), followed by North America ( $I^2 = 97.28\%$ ).

304



305

306

**Figure 6.** Antibiotic use by region

307

**Antibiotic use by study design**

309


310 Prospective cohort studies had the highest estimate of antibiotic prescribing prevalence  
 311 (77.83%, 95% CI 68.09 – 86.23), followed by retrospective cohort studies (56.02%, 95% CI  
 312 39.40 – 71.97) (**Figure 7**). Heterogeneity was considerable in both Retrospective and  
 313 Prospective cohort studies, with  $I^2$  value of 99.72% and 97.82%, respectively.

314

315

316

317



318

319

**Figure 7.** Antibiotic use by study design

320

**Bias assessment**

321

322

323

324

325

326


327

328

329

As detected by the funnel plots generated (**Figure 8**), there was no evidence of publication bias. This is further supported by the objective results (p-values) obtained through Egger's asymmetry test for studies in both prevalence of bacterial coinfection and antibiotic use, p-values were 0.43 and 0.59.

330 ??  
331



332  
333  
334  
335

**Figure 8.** Funnel plots illustrating the assessment of publication bias for each primary outcome

336  
337

## 4- Discussion

338  
339  
340  
341  
342  
343  
344

This systematic review and meta-analysis aimed at determining the prevalence of bacterial coinfection and antibiotic use in COVID-19 patients. The prevalence of bacterial coinfection amongst COVID-19 patients was 5.62% (95% CI 2.26 – 10.31) whilst, the use of antibiotic agents amongst COVID-19 patients was 61.77% (CI 50.95 – 70.90). To the best of the authors' knowledge, this is the first meta-analysis to investigate both outcomes at once as well as break the findings down by Region to provide future guidance.

345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358

With regards to bacterial coinfection in COVID-19 patients, the findings in this review is consistent with those of previously published studies and smaller systematic reviews addressing this issue (Range <4% - 8%)<sup>[9, 30-32]</sup>. Bacterial coinfection prevalence were low across all included studies, with the exception to Contou *et al*, Neto *et al* and Puzniak *et al* in which the reported prevalence rates were 28%, 19% and 16% respectively<sup>[39, 43, 45]</sup>. High prevalence rates reported by Contou *et al* can be attributed to the study setting, which was the ICU. Symptomatic patients admitted to the ICU were tested for COVID-19 and for bacteriological pathogens afterwards; consequently, potentially reporting higher prevalence of bacterial coinfection. Nonetheless, Contou D *et al* clearly differentiated in their study design between coinfections and nosocomial infections. Positive microbiological samples conducted within the first 48 hours of admission were labelled as coinfection, whilst positive microbiological samples after 48 hours were considered to be nosocomial ICU-acquired infections<sup>[43]</sup>.

359  
360

Urinary tract infections (UTIs) were the most prevalent source of bacterial coinfection (57%) as reported by Neto *et al*<sup>[45]</sup>. The authors attributed the high UTI rate to the lack of a fixed

361 defining clinical characteristics of bacterial coinfection and to high risk factors for UTIs  
362 amongst the study population, e.g. elderly hospitalised female patients and diabetic patients.  
363 High bacterial coinfection prevalence rates (16%) were reported by Puznik *et al*<sup>[39]</sup>, the  
364 second largest study included in this review, when compared to the low prevalence rates  
365 reported by Russell *et al*<sup>[49]</sup> (0.65%), the largest study in the review. This may be due to a  
366 number of factors. These include the frequency of microbiological investigations, in which,  
367 investigation rates were higher in the study of Puznik *et al*. Interpretation of microbiological  
368 results in which gram-negative bacteria in sputum samples of non-ventilated patients were  
369 taken which may have over-estimated significance of bacterial coinfection<sup>[39]</sup>.

370  
371 The analyses conducted around bacterial coinfection in COVID-19 patients suggests that  
372 bacterial coinfection prevalence rates are lower than seen in previous viral pandemics. During  
373 the 2009 swine flu pandemic, up to 55% of mortalities were as a result of bacterial  
374 pneumonia<sup>46</sup>. Previous pandemics have also reported that *S. pneumoniae*, *β-hemolytic*  
375 *streptococci*, *H. influenzae*, and *S. aureus* were the most commonly identified bacterial co-  
376 pathogens<sup>[13]</sup>. In this review, *S. aureus* has been the most identified bacterial co-pathogen.

377  
378 This review also identified very high antibiotic use in COVID-19 patients, which is consistent  
379 with previous reviews including those of Langford *et al* (2021)<sup>[33]</sup>, which reported a  
380 prevalence of 74.6% (95% CI 68.3-80.0%). Differences between the results seen in this  
381 review and the review of Langford *et al* may be attributed to the fact that the latter review  
382 also included case series with  $\geq 10$  patients. This can potentially be attributed to the time  
383 period of the pandemic in which the studies were conducted. There was scarceness of cohort  
384 studies in the review of Langford *et al* (2021)<sup>[33]</sup>, which is different to our study. This review  
385 also included a wider selection of nations in addition to a larger number of patients.

386  
387 The increase in antibiotic use observed during this pandemic might have impacted and  
388 setback antimicrobial stewardship (AMS) efforts globally, especially in regions where AMS  
389 programmes are just starting as seen in Africa with previous knowledge and resource issues  
390<sup>[61-63]</sup>. This is starting to change in Africa with a growing number of AMS activities to  
391 address identified concerns<sup>[64-66]</sup>. However, remarkably, in certain regions globally,  
392 specifically in Europe, there was a decline in antibiotic use overall in 2020, despite high  
393 antibiotic use in COVID-19 positive patients. This can potentially be attributed to a number  
394 of factors including social distancing measures and reduction in medical activities<sup>[67-69]</sup>.  
395 Nonetheless, inappropriate use of antibiotics during COVID-19 is a potential driver of the  
396 silent AMR pandemic<sup>[24, 70]</sup>. However, with current changes observed in global human  
397 behaviour, relating to personal hygiene, and increased interest in infection control since the  
398 emergence of this pandemic, we should see a rise in AMS activities globally<sup>[71]</sup>.

399  
400 Sub-group analysis based on the key regions demonstrated that the prevalence of reported  
401 bacterial coinfection was higher in North America followed by Asia and Europe at 7.89%,  
402 5.30% and 3.57%, respectively. Antibiotic use was also higher in North America (68.84%),  
403 followed by Europe (60%) and Asia (40.81%). Our hypothesis suggests that the reason for  
404 higher prevalence of bacterial coinfection and antibiotic use in North America is due to the  
405 presence of larger number of studies and patients from the region in this review, in addition  
406 to possibly higher rates of microbiology investigation and over interpretation of microbiology



407 results. Nevertheless, studies from Asia are reporting high use of antibiotics including the  
408 study of Hassan *et al*, which reported extremely high use of antibiotics (92%) in COVID-19  
409 patients<sup>[72]</sup>, however, this study was not included in our meta-analysis as it has not met our  
410 inclusion criteria. We are also aware of more recent studies in Asia reporting high rates since  
411 our analysis<sup>[22, 73]</sup>.

412  
413 In this review, investigating regional distribution of co-infection and antibiotic use was key.  
414 Its significance is directly correlated to the fact that antimicrobial use varies considerably  
415 across regions, albeit some convergence<sup>[74]</sup>. It is quite apparent that high antibiotic  
416 consumption is common in low- and middle-income countries (LMICs) in contrast to high-  
417 income countries (HICs)<sup>[74]</sup>. In addition, AMR rates vary considerably across countries and  
418 regions, with high AMR rates quite evident in regions such as South Asia and Sub-Sahara  
419 Africa, therefore, it was practical, in this review, to breakdown antibiotic usage rates by  
420 region<sup>[75, 76]</sup>.

421  
422 In terms of study design, sub-group analysis has demonstrated that retrospective studies had  
423 higher prevalence of bacterial coinfection than prospective ones at 5.92% vs 3.97%  
424 respectively. Whilst, on the other hand, antibiotic use was higher in prospective than  
425 retrospective studies, 77.83% vs 56.02%, respectively. The main hypothesis that might  
426 explain these variations in prevalence from the main meta-analyses is the study design itself.  
427 Prospective studies had well-defined processes to determine bacterial coinfection in COVID-  
428 19 patients, such as pre-defined clinical characteristics that prompt microbiological  
429 sampling<sup>[49]</sup>; hence likely lower bacterial coinfection rates but higher justifiable antibiotic  
430 use.

431  
432 Despite having 10 out of 22 studies included in this review published in 2021, all the studies  
433 included have been conducted mainly in the first few months of the pandemic (February and  
434 April 2020) with the exception of one study conducted in June 2020<sup>[60]</sup>. The results from this  
435 review demonstrates that there is insufficient evidence supporting considerable empiric  
436 antibiotic prescribing in COVID-19 patients due to a low prevalence of bacterial coinfection.  
437 Nonetheless, antibiotics use was high mirroring the findings in other reviews. As the  
438 pandemic evolves, and new COVID-19 specific therapeutics come into clinical practice, it  
439 will be important to assess their impact on antibiotic use. The early phase of the pandemic  
440 from which most of the published studies to date relate has been characterised by a lack of  
441 specific COVID-19 therapies and it may be as treatment options become available, and the  
442 understanding of the low prevalence of bacterial co-infection becomes more established, that  
443 there will be less reliance or defaulting to antibiotic prescribing. We will be following this up  
444 in future studies.

445

#### 446 ***Strengths and Limitations***

447

448 We believe the key strengths of this review included a comprehensive search strategy  
449 spanning several databases, including both pre-prints and peer-reviewed studies, resulting in  
450 22 studies being included, representing over 76,000 patients.

451

452 However, we are aware that this review was not without limitations. During the screening  
453 process, a significant number of studies have been excluded as they did not meet the  
454 inclusion criteria. The majority of the excluded studies included non-lab confirmed COVID-  
455 19 patients, therefore, bacterial coinfection and antibiotic use may be under- or over-reported.  
456 Disproportionate representation from North America and failure to include studies from  
457 regions other than Europe and Asia can also limit the generalizability of the results to other  
458 regions impacted by COVID-19. Additionally, the majority of studies included were  
459 conducted within the first 6 month of pandemic. Consequently, data included might not be up  
460 to date, which again, can compromise the generalizability of the results. Notably, the  
461 emergence of new variants, updated treatment regimens and variations in measures for  
462 SARS-CoV-2 testing, might impact the prevalence of bacterial coinfection and antibiotic  
463 use<sup>[77]</sup>. In addition, the majority of studies included in the meta-analyses were retrospective  
464 studies with their inherently associated bias and limitations.

465

466 Alongside this, determining the appropriateness and justifiable need of antibiotic therapy,  
467 which is likely to be higher in prospective studies in comparison to retrospective studies, was  
468 not possible, as studies have mainly reported the number of patients prescribed antibiotics.  
469 Information such as indications, initiation timing and duration of antibiotic could assist in  
470 determining future appropriateness. Diagnostic tests and measures used to determine  
471 bacteriological infections were also under-reported. This is crucial to determine whether the  
472 infection is a true infection or bacterial colonisation.

473

474 In addition 3 (13%) of the 22 studies included in this review were non-peer reviewed, which  
475 might raise concerns regarding their quality<sup>[55, 56, 58]</sup>. However, one of these studies is now  
476 published, so it is unlikely to be of low quality<sup>[58]</sup>. The remaining two, despite not being  
477 published, have still attained a “good” quality rating using the NOS, in addition, both studies  
478 weighted in the forest plot were small, and therefore unlikely to affect the overall results

479

480 Future reviews and studies should aim at diversifying study regions, and to include or  
481 conduct studies that are more up to date. Studies should also include data on the  
482 appropriateness of antibiotic therapy, diagnostic tests and measures used to determine the  
483 infection. However, despite these limitations, we believe the findings give good guidance  
484 regarding the need to improve the rationality of antibiotic prescribing in patients with  
485 COVID-19 to reduce the occurrence of AMR within facilities.

486

## 487 **Conclusion**

488

489 This study demonstrates that the prevalence of bacterial coinfection amongst COVID-19  
490 patients was low, 5.62%, nevertheless, antibiotics use amongst COVID-19 patients was high  
491 (61.77%). The findings of this study encourage a more rational approach to antibiotics  
492 prescribing in COVID-19 patients, an approach based on laboratory-confirmed diagnosis of  
493 coinfection, rather than clinical, advocating for more antimicrobial stewardship (AMS). We  
494 know that antimicrobial stewardship programmes have been successfully instigated across  
495 countries including LMICs, and we will be looking to build on this.

496

497 **Statements and Declarations**

498 **Funding**

499 *The authors declare that no funds, grants, or other support were received during the*  
500 *preparation of this manuscript*

501

502 **Competing Interests**

503 *The authors have no relevant financial or non-financial interests to disclose*

504

505 **Author Contributions**

506 *Data collection and analysis were performed by Faisal Alshaikh, Oula Sindi and Amanj*  
507 *Kurdi. The first draft of the manuscript was written by Faisal Alshaikh and all authors*  
508 *commented on previous versions of the manuscript. All authors read and approved the final*  
509 *manuscript*

510

511 **Data Availability**

512 *All data generated or analysed during this study are included in this published article*

513

514 **Ethics approval**

515 *Not applicable*

516

517 **Consent to participate**

518 *Not applicable*

519

520 **Consent to publish**

521 *Not applicable*

## 522 **References**

523

- 524 1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in  
525 Wuhan, China, of novel coronavirus–infected pneumonia. *New England journal of medicine*.  
526 2020.
- 527 2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus  
528 disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the  
529 Chinese Center for Disease Control and Prevention. *Jama*. 2020;323(13):1239-42.
- 530 3. WHO. WHO Coronavirus (COVID-19) Dashboard 2022, January 02 [Available from:  
531 <https://covid19.who.int/>].
- 532 4. Harris M, Bagozzi D. WHO discontinues hydroxychloroquine and lopinavir/ritonavir  
533 treatment arms for COVID-19. *World Heal Organ News Release*. 2020.
- 534 5. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of  
535 hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a  
536 multi-centre, randomized, controlled trial. *MedRxiv*. 2020.
- 537 6. Group RC. Dexamethasone in hospitalized patients with Covid-19. *New England*  
538 *Journal of Medicine*. 2021;384(8):693-704.
- 539 7. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al.  
540 Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa:  
541 caution for inappropriate off-label use in healthcare settings. *The American journal of*  
542 *tropical medicine and hygiene*. 2020;102(6):1184-8.
- 543 8. Sefah IA, Ogunleye OO, Essah DO, Opanga SA, Butt N, Wamaitha A, et al. Rapid  
544 assessment of the potential paucity and price increases for suggested medicines and  
545 protection equipment for COVID-19 across developing countries with a particular focus on  
546 Africa and the implications. *Frontiers in pharmacology*. 2021;11:2055.
- 547 9. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a  
548 systematic review and meta-analysis. *Journal of Infection*. 2020;81(2):266-75.
- 549 10. Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with  
550 influenza pandemics. *Frontiers in microbiology*. 2017;8:1041.
- 551 11. Gupta RK, George R, Nguyen-Van-Tam JS. Bacterial pneumonia and pandemic  
552 influenza planning. *Emerging infectious diseases*. 2008;14(8):1187.
- 553 12. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R,  
554 Villavicencio C, et al. Community-acquired respiratory coinfection in critically ill patients  
555 with pandemic 2009 influenza A (H1N1) virus. *Chest*. 2011;139(3):555-62.
- 556 13. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as  
557 a cause of death in pandemic influenza: implications for pandemic influenza preparedness.  
558 *The Journal of infectious diseases*. 2008;198(7):962-70.
- 559 14. Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with  
560 influenza. *Influenza and other respiratory viruses*. 2013;7:105-13.
- 561 15. Assiri A, Al-Tawfiq JA, Al-Rabeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et  
562 al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East  
563 respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *The Lancet*  
564 *infectious diseases*. 2013;13(9):752-61.
- 565 16. Zahariadis G, Gooley TA, Ryall P, Hutchinson C, Latchford MI, Fearon MA, et al.  
566 Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: variable  
567 incidence of atypical bacteria coinfection based on diagnostic assays. *Canadian respiratory*  
568 *journal*. 2006;13(1):17-22.
- 569 17. Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, et al.  
570 Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective  
571 cohort study. *Critical care medicine*. 2017;45(10):1683-95.

- 572 18. Grau S, Hernández S, Echeverría-Esnal D, Almendral A, Ferrer R, Limón E, et al.  
573 Antimicrobial consumption among 66 acute care hospitals in Catalonia: impact of the  
574 COVID-19 pandemic. *Antibiotics*. 2021;10(8):943.
- 575 19. Mustafa ZU, Salman M, Aldeyab M, Kow CS, Hasan SS. Antimicrobial consumption  
576 among hospitalized patients with COVID-19 in Pakistan. *SN comprehensive clinical*  
577 *medicine*. 2021:1-5.
- 578 20. Molla MMA, Yeasmin M, Islam MK, Sharif MM, Amin MR, Nafisa T, et al.  
579 Antibiotic Prescribing Patterns at COVID-19 Dedicated Wards in Bangladesh: Findings from  
580 a Single Center Study. *Infection Prevention in Practice*. 2021;3(2):100134.
- 581 21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for  
582 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.  
583 *The lancet*. 2020;395(10229):1054-62.
- 584 22. Chowdhury K, Haque M, Nusrat N, Adnan N, Islam S, Lutfor AB, et al. Management  
585 of children admitted to hospitals across Bangladesh with suspected or confirmed COVID-19  
586 and the implications for the future: a nationwide cross-sectional study. *Antibiotics*.  
587 2022;11(1):105.
- 588 23. Caselli E. Hygiene: microbial strategies to reduce pathogens and drug resistance in  
589 clinical settings. *Microbial Biotechnology*. 2017;10(5):1079-83.
- 590 24. Founou RC, Blocker AJ, Noubom M, Tsayem C, Choukem SP, Dongen MV, et al.  
591 The COVID-19 pandemic: a threat to antimicrobial resistance containment. *Future Science*  
592 *OA*. 2021(0):FSO736.
- 593 25. Hsu J. How covid-19 is accelerating the threat of antimicrobial resistance. *Bmj*.  
594 2020;369.
- 595 26. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al.  
596 Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-  
597 resistant bacteria in the EU and the European Economic Area in 2015: a population-level  
598 modelling analysis. *The Lancet infectious diseases*. 2019;19(1):56-66.
- 599 27. Hofer U. The cost of antimicrobial resistance. *Nature Reviews Microbiology*.  
600 2019;17(1):3-.
- 601 28. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, et al.  
602 Strategies to improve antimicrobial utilization with a special focus on developing countries.  
603 *Life*. 2021;11(6):528.
- 604 29. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic  
605 resistance in developing countries: a systematic review and meta-analysis. *PloS one*.  
606 2017;12(12):e0189621.
- 607 30. Westblade LF, Simon MS, Satlin MJ. Bacterial Co-Infections in Coronavirus Disease  
608 2019. *Trends in microbiology*. 2021.
- 609 31. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al.  
610 Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid  
611 review and meta-analysis. *Clinical Microbiology and Infection*. 2020.
- 612 32. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N.  
613 Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other  
614 pathogens: A systematic review and meta-analysis. *PloS one*. 2021;16(5):e0251170.
- 615 33. Langford BJ, So M, Raybardhan S, Leung V, Soucy J-PR, Westwood D, et al.  
616 Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clinical*  
617 *Microbiology and Infection*. 2021.
- 618 34. Iwu CJ, Jordan P, Jaja IF, Iwu CD, Wiysonge CS. Treatment of COVID-19:  
619 implications for antimicrobial resistance in Africa. *The Pan African Medical Journal*.  
620 2020;35(Suppl 2).

- 621 35. Institute OHR. The Newcastle-Ottawa Scale (NOS) for assessing the quality of  
622 nonrandomised studies in meta-analyses 2021 [Available from: The Newcastle-Ottawa Scale  
623 (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
- 624 36. Freeman MF, Tukey JW. Transformations related to the angular and the square root.  
625 *The Annals of Mathematical Statistics*. 1950;607-11.
- 626 37. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials:  
627 an update. *Contemporary clinical trials*. 2007;28(2):105-14.
- 628 38. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other  
629 sample size effects in systematic reviews of diagnostic test accuracy was assessed. *Journal of*  
630 *clinical epidemiology*. 2005;58(9):882-93.
- 631 39. Puzniak L, Finelli L, Kalvin CY, Bauer KA, Moise P, De Anda C, et al. A multicenter  
632 analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the  
633 US with or without COVID-19. *BMC infectious diseases*. 2021;21(1):1-9.
- 634 40. Wang L, Amin AK, Khanna P, Aali A, McGregor A, Bassett P, et al. An  
635 observational cohort study of bacterial co-infection and implications for empirical antibiotic  
636 therapy in patients presenting with COVID-19 to hospitals in North West London. *Journal of*  
637 *Antimicrobial Chemotherapy*. 2021;76(3):796-803.
- 638 41. Pulia MS, Wolf I, Schwei RJ, Chen D, Lepak AJ, Schulz LT, et al. Antibiotic  
639 prescribing patterns for coronavirus disease 2019 (COVID-19) in two emergency  
640 departments with rapid procalcitonin. *Infection Control & Hospital Epidemiology*.  
641 2021;42(3):359-61.
- 642 42. Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal  
643 coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a  
644 UK secondary-care setting. *Clinical Microbiology and Infection*. 2020;26(10):1395-9.
- 645 43. Contou D, Claudinon A, Pajot O, Micaëlo M, Flandre PL, Dubert M, et al. Bacterial  
646 and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French  
647 ICU. *Annals of intensive care*. 2020;10(1):1-9.
- 648 44. Cheng LS-k, Chau SK-y, Tso EY-k, Tsang SW-c, Li IY-f, Wong BK-c, et al.  
649 Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19:  
650 experience from a single hospital cluster. *Therapeutic Advances in Infectious Disease*.  
651 2020;7:2049936120978095.
- 652 45. Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy III R, et  
653 al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. *Journal of*  
654 *medical virology*. 2021;93(3):1489-95.
- 655 46. Lardaro T, Wang AZ, Bucca A, Croft A, Globler N, Holt DB, et al. Characteristics of  
656 COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency  
657 department in a large regional healthcare system. *Journal of Medical Virology*.  
658 2021;93(5):2883-9.
- 659 47. Chen S, Zhu Q, Xiao Y, Wu C, Jiang Z, Liu L, et al. Clinical and etiological analysis  
660 of co-infections and secondary infections in COVID-19 patients: An observational study.  
661 *The Clinical Respiratory Journal*. 2021.
- 662 48. Baskaran V, Lawrence H, Lansbury LE, Webb K, Safavi S, Zainuddin NI, et al. Co-  
663 infection in critically ill patients with COVID-19: an observational cohort study from  
664 England. *Journal of medical microbiology*. 2021;70(4).
- 665 49. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al. Co-  
666 infections, secondary infections, and antimicrobial usage in hospitalised patients with  
667 COVID-19 from the ISARIC WHO CCP-UK study: a prospective, multicentre cohort study.  
668 2021.

- 669 50. Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community-acquired  
670 coinfection in coronavirus disease 2019: A retrospective observational experience. *Clinical*  
671 *Infectious Diseases*. 2021;72(8):1450-2.
- 672 51. Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric  
673 antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with  
674 coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. *Clinical Infectious*  
675 *Diseases*. 2021;72(10):e533-e41.
- 676 52. Miao Q, Ma Y, Ling Y, Jin W, Su Y, Wang Q, et al. Evaluation of superinfection,  
677 antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19  
678 patients: A cohort study in Shanghai. *Journal of Microbiology, Immunology and Infection*.  
679 2021.
- 680 53. Karami Z, Knoop BT, Dofferhoff AS, Blaauw MJ, Janssen NA, van Apeldoorn M, et  
681 al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of  
682 hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in  
683 The Netherlands. *Infectious Diseases*. 2021;53(2):102-10.
- 684 54. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N,  
685 Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients  
686 with COVID-19: a retrospective cohort study. *Clinical Microbiology and Infection*.  
687 2021;27(1):83-8.
- 688 55. Crotty MP, Dominguez EA, Akins R, Nguyen AT, Slika R, Rahmzadeh K, et al.  
689 Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in  
690 hospitalized patients. *medRxiv*. 2020.
- 691 56. Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC. Limited role for  
692 antibiotics in COVID-19: scarce evidence of bacterial coinfection. Available at SSRN  
693 3622388. 2020.
- 694 57. Karaba SM, Jones G, Hesel T, Smith LL, Avery R, Dzintars K, et al., editors.  
695 Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a  
696 multicenter study. *Open forum infectious diseases*; 2021: Oxford University Press US.
- 697 58. Martin AJ, Shulder S, Dobrzynski D, Quartuccio K, Pillinger KE. Rate of Antibiotic  
698 Use and Associated Risk Factors in COVID-19 Hospitalized Patients. *medRxiv*. 2020.
- 699 59. Rothe K, Feihl S, Schneider J, Wallnöfer F, Wurst M, Lukas M, et al. Rates of  
700 bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort  
701 study in light of antibiotic stewardship. *European Journal of Clinical Microbiology &*  
702 *Infectious Diseases*. 2021;40(4):859-69.
- 703 60. Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum  
704 PA, et al. The clinical impact of bacterial co-infection among moderate, severe and critically  
705 ill COVID-19 patients in the second referral hospital in Surabaya. *F1000Research*. 2021;10.
- 706 61. Fadare JO, Ogunleye O, Iliyasu G, Adeoti A, Schellack N, Engler D, et al. Status of  
707 antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: findings and  
708 implications. *Journal of global antimicrobial resistance*. 2019;17:132-6.
- 709 62. Kalungia AC, Mwambula H, Munkombwe D, Marshall S, Schellack N, May C, et al.  
710 Antimicrobial stewardship knowledge and perception among physicians and pharmacists at  
711 leading tertiary teaching hospitals in Zambia: implications for future policy and practice.  
712 *Journal of chemotherapy*. 2019;31(7-8):378-87.
- 713 63. Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas MV, et al.  
714 Antibiotic stewardship in low-and middle-income countries: the same but different? *Clinical*  
715 *microbiology and infection*. 2017;23(11):812-8.
- 716 64. Sneddon J, Cooper L, Afriyie DK, Sefah IA, Cockburn A, Kerr F, et al. Supporting  
717 antimicrobial stewardship in Ghana: Evaluation of the impact of training on knowledge and

- 718 attitudes of healthcare professionals in two hospitals. *JAC-antimicrobial resistance*.  
719 2020;2(4):dlaa092.
- 720 65. D'Arcy N, Ashiru-Oredope D, Olaoye O, Afriyie D, Akello Z, Ankrah D, et al.  
721 Antibiotic Prescribing Patterns in Ghana, Uganda, Zambia and Tanzania Hospitals: Results  
722 from the Global Point Prevalence Survey (G-PPS) on Antimicrobial Use and Stewardship  
723 Interventions Implemented. *Antibiotics*. 2021;10(9):1122.
- 724 66. Akpan MR, Isemin NU, Udoh AE, Ashiru-Oredope D. Implementation of  
725 antimicrobial stewardship programmes in African countries: a systematic literature review.  
726 *Journal of global antimicrobial resistance*. 2020;22:317-24.
- 727 67. Scotland HP. SONAAR report for 2020. NHS Scotland 2021 16 November 2021.
- 728 68. Agency UHS. English surveillance programme for antimicrobial utilisation and  
729 resistance (ESPAUR) Report for 2020 to 2021. England; 2021. Contract No.: GOV-9892.
- 730 69. (ECDC) ECfDPaC. Surveillance of antimicrobial resistance in Europe, 2020 data.  
731 2021.
- 732 70. Nusrat N, Haque M, Chowdhury K, Adnan N, Lutfor AB, Karim E, et al. Pilot study  
733 on the current management of children with COVID-19 in hospitals in Bangladesh; findings  
734 and implications. *Bangladesh Journal of Medical Science*. 2021:188-98.
- 735 71. Huttner B, Catho G, Pano-Pardo J, Pulcini C, Schouten J. COVID-19: don't neglect  
736 antimicrobial stewardship principles! *Clinical Microbiology and Infection*. 2020;26(7):808.
- 737 72. Hassan M, Biswas M, Al Jubayer A, Rahman F, Akhtar Z, Das P, et al. Use of  
738 Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh:  
739 Findings from the First Wave of COVID-19 Pandemic. *Antibiotics*. 2021;10(6):738.
- 740 73. Kumar S, Haque M, Shetty A, Acharya J, Kumar M, Sinha VK, et al. Current  
741 management of children with COVID-19 in hospitals in India; pilot study and findings.  
742 *Advances in Human Biology*. 2021.
- 743 74. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global  
744 increase and geographic convergence in antibiotic consumption between 2000 and 2015.  
745 *Proceedings of the National Academy of Sciences*. 2018;115(15):E3463-E70.
- 746 75. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global  
747 burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*. 2022.
- 748 76. Sriram A KE KG, Craig J, Balasubramanian R, Brar S et al. A global analysis of  
749 antimicrobial resistance and its drivers. Center for Disease Dynamics, Economics & Policy.  
750 Washington, DC; 2021 2021.
- 751 77. Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2  
752 Variants, Vaccines and Therapeutic Strategies. 2021.

753

754



755 **Appendices**

756

757 *Appendix 1: Key search strategy*

758

759 **Embase (OVID)**

760

	<b>Searches</b>	<b>Results</b>
1	coronavirus disease 2019.ti,ab,kw.	25682
2	covid-19.ti,ab,kw.	130651
3	severe acute respiratory syndrome coronavirus 2.ti,ab,kw.	14082
4	1 or 2 or 3	134431
5	mixed infection.ti,ab,kw.	4870
6	co-infection.ti,ab,kw.	18590
7	5 or 6	23284
8	antibiotic agent.ti,ab,kw.	766
9	antimicrobial therapy.ti,ab,kw.	18563
10	antimicrobial activity.ti,ab,kw.	46766
11	antibacterial activity.ti,ab,kw.	46261
12	antiinfective agent.ti,ab,kw.	31
13	8 or 9 or 10 or 11 or 12	103731
14	7 or 13	126880
15	4 and 14	463
16	prevalence/	793668
17	Observational Studies/ or observational.ti,ab.	384858
18	prospective studies/ or retrospective studies/ or prospective.ti,ab. or retrospective.ti,ab.	2326072
19	randomized controlled trial/	665355
20	16 or 17 or 18 or 19	3703038
21	15 and 20	151
22	limit 21 to (human and yr="2019 -Current")	149
23	limit 22 to english language	147

761

762

763

764 **MedLine (OVID)**

765

	<b>Searches</b>	<b>Results</b>
1	COVID-19/	88096
2	Coronavirus Infections/	44949
3	SARS-CoV-2/	68317
4	covid*.ti,ab,kw.	134027
5	coronavirus*.ti,ab,kw.	68550
6	ncov*.ti,ab,kw.	1606
7	sars*.ti,ab,kw.	60031
8	severe acute respiratory syndrome coronavir*.ti,ab,kw.	16722
9	"2019 ncov*" .ti,ab,kw.	1682
10	nCOV19*.ti,ab,kw.	9
11	SARSCoV2*.ti,ab,kw.	45
12	"sars cov2*" .ti,ab,kw.	2059
13	"coronavirus 19*" .ti,ab,kw.	290
14	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13	170734
15	Coinfection/	12379
16	coinfect*.ti,ab,kw.	15898
17	co-infect*.ti,ab,kw.	18471
18	"mixed infecti*" .ti,ab,kw.	7718
19	"bacterial coinfect*" .ti,ab,kw.	311
20	"bacterial co-infect*" .ti,ab,kw.	365
21	15 or 16 or 17 or 18 or 19 or 20	44285
22	Anti-Bacterial Agents/	354528
23	Anti-Infective Agents/	56119
24	antimicrob*.ti,ab,kw.	184372
25	anti-microb*.ti,ab,kw.	4930
26	antiinfect*.ti,ab,kw.	798
27	anti-infect*.ti,ab,kw.	7984
28	antibact*.ti,ab,kw.	84949
29	anti-bact*.ti,ab,kw.	4701
30	antibiot*.ti,ab,kw.	372008
31	22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30	710470
32	21 or 31	751355
33	14 and 32	4117
34	prevalence/	311186
35	Observational Studies/ or Observational.ti,ab,kw.	203842
36	prospective studies/ or retrospective studies/ or prospective.ti,ab,kw. or retrospective.ti,ab,kw.	1880121
37	randomized controlled trial/	535869
38	34 or 35 or 36 or 37	2654657
39	33 and 38	836
40	limit 39 to (english language and humans and yr="2019 - 2022")	461

766 **Cochrane**

767

<b>ID</b>	<b>Search</b>	<b>Hits</b>
#1	MeSH descriptor: [COVID-19] this term only	398
#2	MeSH descriptor: [Severe Acute Respiratory Syndrome] this term only	358
#3	MeSH descriptor: [SARS-CoV-2] this term only	294
#4	(covid*):ti,ab,kw	5941
#5	(corona*):ti,ab,kw	65223
#6	(coronavirus*):ti,ab,kw	3372
#7	(coronavirus infect*):ti,ab,kw	2051
#8	("SARS-Co-V*"):ti,ab,kw	2144
#9	("severe acute respiratory syndrome coronavirus*"):ti,ab,kw	489
#10	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9	68000
#11	MeSH descriptor: [Coinfection] this term only	210
#12	MeSH descriptor: [Bacterial Infections] this term only	3191
#13	MeSH descriptor: [Respiratory Tract Infections] this term only	2323
#14	(coinfect*):ti,ab,kw	1606
#15	(co-infect*):ti,ab,kw	965
#16	("co infect*"):ti,ab,kw	1
#17	("mixed infection*"):ti,ab,kw	579
#18	("respiratory infection*"):ti,ab,kw	1323
#19	#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18	8180
#20	MeSH descriptor: [Anti-Bacterial Agents] this term only	11188
#21	MeSH descriptor: [Antibiotic Prophylaxis] this term only	1301
#22	MeSH descriptor: [Anti-Infective Agents] this term only	2715
#23	(antibiotic*):ti,ab,kw	32360
#24	(antimicrobial*):ti,ab,kw	7832
#25	("antimicrobial drug*"):ti,ab,kw	82
#26	("antibiotic drug*"):ti,ab,kw	55
#27	("antibiotic agent*"):ti,ab,kw	2527
#28	("empirical antibiotic*"):ti,ab,kw	166
#29	("prophylactic antibiotic*"):ti,ab,kw	635
#30	#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29	42620
#31	#19 OR #30	47991
#32	#10 AND #31	822
#33	#32 with Cochrane Library publication date Between Nov 2019 and Jun 2021	392
#34	#33 in Cochrane Reviews, Trials	392

768

769 **MedRXiv**


770

771 Full text or abstract or title "covid-19 AND (Antibiotic OR Coinfection)" (match whole all)

772 and posted between "01 Dec, 2019 and 14 Jun, 2021" Results: **182**


773

774



**Fig a.** Prevalence of Bacterial coinfection in Prospective Cohort Studies

775  
776  
777



**Figure b.** Prevalence of antibiotic use in Asia

778  
779